多臂试验中不同处理组不进行多重检验：原理与理由。
Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification.
机构信息
Edinburgh Clinical Trials Unit, Usher Institute, The University of Edinburgh, Edinburgh, UK.
出版信息
Clin Trials. 2020 Oct;17(5):562-566. doi: 10.1177/1740774520941419. Epub 2020 Jul 15.
Abstract
There is currently a lack of consensus and uncertainty about whether one should adjust for multiple testing in multi-arm trials of distinct treatments. A detailed rationale is presented to justify non-adjustment in this situation. We argue that non-adjustment should be the default starting position in simple multi-arm trials of distinct treatments.
摘要
目前，对于是否应该在不同治疗方法的多臂试验中进行多次检验调整，尚未达成共识且存在不确定性。本文提出了详细的基本原理来证明在这种情况下不进行调整是合理的。我们认为，在简单的不同治疗方法的多臂试验中，不进行调整应该是默认的起始立场。
相似文献
1
Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification.多臂试验中不同处理组不进行多重检验：原理与理由。
Clin Trials. 2020 Oct;17(5):562-566. doi: 10.1177/1740774520941419. Epub 2020 Jul 15.
2
Controlling the family-wise error rate in multi-arm, multi-stage trials.在多臂多阶段试验中控制家族性错误率。
Clin Trials. 2017 Jun;14(3):237-245. doi: 10.1177/1740774517694130. Epub 2017 Mar 19.
3
Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: Clear guidance is needed.在共享对照组的平行组多臂试验中进行多样性调整：需要明确的指导。
Contemp Clin Trials. 2022 Feb;113:106656. doi: 10.1016/j.cct.2021.106656. Epub 2021 Dec 11.
4
Adding experimental treatment arms to multi-arm multi-stage platform trials in progress.在多臂多阶段平台试验进行中增加试验治疗组。
Stat Med. 2024 Aug 15;43(18):3447-3462. doi: 10.1002/sim.10090. Epub 2024 Jun 9.
5
A web application for the design of multi-arm clinical trials.一个用于设计多臂临床试验的网络应用程序。
BMC Cancer. 2020 Jan 31;20(1):80. doi: 10.1186/s12885-020-6525-0.
6
Recommendations on multiple testing adjustment in multi-arm trials with a shared control group.多臂试验中具有共享对照组时的多重检验调整建议。
Stat Methods Med Res. 2018 May;27(5):1513-1530. doi: 10.1177/0962280216664759. Epub 2016 Sep 19.
7
Recommendations for designing and analysing multi-arm non-inferiority trials: a review of methodology and current practice.多臂非劣效性试验的设计和分析建议：方法学和当前实践综述。
Trials. 2021 Jun 26;22(1):417. doi: 10.1186/s13063-021-05364-9.
8
The issue of multiplicity in noninferiority studies.非劣效性研究中的多重性问题。
Clin Trials. 2012 Dec;9(6):730-5. doi: 10.1177/1740774512455370. Epub 2012 Aug 9.
9
Design, analysis and reporting of multi-arm trials and strategies to address multiple testing.多臂试验的设计、分析和报告以及应对多次检验的策略。
Int J Epidemiol. 2020 Jun 1;49(3):968-978. doi: 10.1093/ije/dyaa026.
10
Traditional multiplicity adjustment methods in clinical trials.临床试验中的传统多重性调整方法。
Stat Med. 2013 Dec 20;32(29):5172-218. doi: 10.1002/sim.5990. Epub 2013 Sep 30.
引用本文的文献
1
Design Considerations for a Phase II Platform Trial in Major Depressive Disorder.重度抑郁症II期平台试验的设计考量
Pharm Stat. 2025 Sep-Oct;24(5):e70025. doi: 10.1002/pst.70025.
2
Overcoming Barriers to Exclusive Breastfeeding in Lao PDR: Social Transfer Intervention Randomised Controlled Trial.克服老挝人民民主共和国纯母乳喂养障碍：社会转移干预随机对照试验
Nutrients. 2025 Jul 22;17(15):2396. doi: 10.3390/nu17152396.
3
An Epidemiologic Approach for Estimating Risk Reduction and Asymptotic Power on the Log-Difference Scale.一种用于估计对数差异尺度上风险降低和渐近功效的流行病学方法。
Int J Environ Res Public Health. 2025 May 1;22(5):719. doi: 10.3390/ijerph22050719.
4
Master protocol for a series of cohort-based randomized controlled trials to test tools to communicate research results to study participants and others with relevant lived experience: the SPIN-CLEAR Trials.一系列基于队列的随机对照试验的主方案，旨在测试向研究参与者及其他有相关实际经验的人传达研究结果的工具：SPIN-CLEAR试验。
Trials. 2025 May 8;26(1):149. doi: 10.1186/s13063-025-08846-2.
5
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials.哮喘发作的炎症和临床危险因素（ORACLE2）：22项随机试验对照组的患者水平荟萃分析。
Lancet Respir Med. 2025 Jun;13(6):505-516. doi: 10.1016/S2213-2600(25)00037-2. Epub 2025 Apr 8.
6
Limitation of site-stratified cox regression analysis in survival data: a cautionary tale of the PANAMO phase III randomized, controlled study in critically ill COVID-19 patients.生存数据中位点分层Cox回归分析的局限性：关于重症COVID-19患者的PANAMO III期随机对照研究的警示故事
Trials. 2024 Dec 18;25(1):822. doi: 10.1186/s13063-024-08679-5.
7
Conditional and Unconditional Social Transfers, Early-Life Nutrition, and Child Growth: A Randomized Clinical Trial.有条件和无条件社会转移支付、早期营养与儿童生长发育：一项随机临床试验
JAMA Pediatr. 2025 Feb 1;179(2):129-136. doi: 10.1001/jamapediatrics.2024.5079.
8
Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.硝苯地平与拉贝洛尔口服治疗轻度慢性高血压的妊娠结局比较。
Obstet Gynecol. 2024 Jul 1;144(1):126-134. doi: 10.1097/AOG.0000000000005613. Epub 2024 May 23.
9
Design of a dual randomized trial in a type 2 hybrid effectiveness-implementation study.在 2 型混合有效性-实施研究中设计一项双重随机试验。
Implement Sci. 2023 Nov 23;18(1):64. doi: 10.1186/s13012-023-01317-9.
10
Predicting Fear Extinction in Posttraumatic Stress Disorder.预测创伤后应激障碍中的恐惧消退
Brain Sci. 2023 Jul 28;13(8):1131. doi: 10.3390/brainsci13081131.
本文引用的文献
1
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.三种神经保护药物在继发进展型多发性硬化症（MS-SMART）中的疗效：一项 2b 期、多臂、双盲、随机安慰剂对照试验。
Lancet Neurol. 2020 Mar;19(3):214-225. doi: 10.1016/S1474-4422(19)30485-5. Epub 2020 Jan 22.
2
TAME trial: a multi-arm phase II randomised trial of four novel interventions for malnutrition enteropathy in Zambia and Zimbabwe - a study protocol.TAME试验：赞比亚和津巴布韦针对营养不良性肠病的四种新型干预措施的多臂II期随机试验——研究方案
BMJ Open. 2019 Nov 14;9(11):e027548. doi: 10.1136/bmjopen-2018-027548.
3
Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement.多臂平行组随机试验报告：CONSORT 2010 声明的扩展。
JAMA. 2019 Apr 23;321(16):1610-1620. doi: 10.1001/jama.2019.3087.
4
On the need to adjust for multiplicity in confirmatory clinical trials with master protocols.关于在采用主方案的确证性临床试验中对多重性进行调整的必要性。
Ann Oncol. 2019 Apr 1;30(4):506-509. doi: 10.1093/annonc/mdz038.
5
P values in display items are ubiquitous and almost invariably significant: A survey of top science journals.显示项中的 P 值无处不在，几乎总是具有统计学意义：对顶级科学期刊的调查。
PLoS One. 2018 May 15;13(5):e0197440. doi: 10.1371/journal.pone.0197440. eCollection 2018.
6
An introduction to multiplicity issues in clinical trials: the what, why, when and how.临床试验中多重性问题简介：是什么、为什么、何时以及如何。
Int J Epidemiol. 2017 Apr 1;46(2):746-755. doi: 10.1093/ije/dyw320.
7
Recommendations on multiple testing adjustment in multi-arm trials with a shared control group.多臂试验中具有共享对照组时的多重检验调整建议。
Stat Methods Med Res. 2018 May;27(5):1513-1530. doi: 10.1177/0962280216664759. Epub 2016 Sep 19.
8
Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims.为什么两个错误并不比一个错误更糟糕？关于控制虚假声明预期数量的一项提议。
Pharm Stat. 2016 Jul;15(4):362-7. doi: 10.1002/pst.1751. Epub 2016 Apr 20.
9
How to test hypotheses if you must.如果你必须这样做，该如何检验假设。
Pharm Stat. 2015 Mar-Apr;14(2):139-50. doi: 10.1002/pst.1667. Epub 2015 Jan 7.
10
Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?多臂试验中的多重检验校正：是否必要以及是否进行了校正？
Trials. 2014 Sep 17;15:364. doi: 10.1186/1745-6215-15-364.
Zotero 插件